NCT02132247已完成4 期
An Open-label, Prospective, Uncontrolled Study of the Safety and Local Tolerability of the Diclofenac Epolamine Patch (Flector Patch) in Pediatric Patients With Minor Soft Tissue Injuries
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 104
- 试验地点
- 10
- 主要终点
- Dermatologic Assessment at the Patch Application Site
研究概览
简要总结
The primary purpose of this study is to determine whether Flector Patch is safe for use in children. The secondary purpose is to assess blood levels of diclofenac, the active ingredient in Flector Patch.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Years 至 16 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 6 to 16 years, either gender
- •Informed consent: 6-9 year olds must have their parent/legally authorized representative complete a Parental Permission Form; 10-16 year olds must complete a Children's Assent Form and have their parent/legally authorized representative complete a Parental Permission Form
- •Minor soft tissue injury within 96 hours of study entry
- •Spontaneous pain of at least moderate intensity (i.e. pain of at least 3 on the 6-point Wong- Baker Faces scale for pain severity assessment by patient)
- •Injury must be considered by the Investigator to be clinically significant
- •Negative urine pregnancy test at screening for female subjects of childbearing potential (started the menstrual cycle)
- •Able to read and speak English
- •Available with their parents for the immediate two week period following study enrollment
排除标准
- •Major soft tissue injury (Fractures are only exclusionary if the injury is stabilized with a device, e.g. a hard cast, that cannot be removed to allow a patch to be applied to the site of injury)
- •Open skin lesion or any dermatological condition (e.g. skin infection, eczema) within the injured area
- •Injury is midline or involves the spine, digits or hands
- •Prior injury to the same site within the past 3 months
- •Three or more other prior injuries (minor or major) to the region in the past
- •Injury occurred more than 96 hours prior to study entry
- •Prior use of topical medication to involved area within 48 hours of study entry
- •Allergic disorders, including asthma or urticaria, but only if associated with exposure to aspirin or an NSAID
- •Coagulation defects
- •Prior use of over-the-counter (OTC) analgesics or short-acting non-steroidal anti-inflammatory drugs (NSAIDs [ibuprofen, ketoprofen]) within 6 hours of study entry (acetaminophen permitted up until the time of study entry)
- •Prior use of narcotic analgesics within 7 days of study entry
- •Prior use of systemic anti-inflammatory steroidal drugs within 60 days of study entry
- •Prior use of long-acting NSAIDs such as piroxicam or naproxen since injury
- •Concomitant use of drugs which may be susceptible to interactions with diclofenac, or affect safety if used concomitantly (serotonin-selective reuptake inhibitors (SSRI), lithium, digoxin, anticoagulants, antidiabetic agents, cyclosporin, methotrexate, quinolone antimicrobials, other NSAIDs, steroids and diuretics)
- •Subjects suffering from psychiatric disorders (including depression)
- •Handicapped patients, but only if the handicap prevents them from either assessing their pain or safely using the patch (e.g., pervasive developmental disorders such as autism, Asperger syndrome, Rett syndrome, Heller's syndrome, severe attention deficit hyperactivity disorders (ADHD), other severe mental retardation of traumatic, congenital or other origin)
- •History of current alcohol or drug abuse dated < 1 year
- •Severe cardiac, renal or hepatic impairment
- •Severe systemic diseases (e.g. cancer, severe acute infection)
- •Any underlying disease or medication that severely compromise the patient's immune system
- •Prior history of any chronic pain disorder
- •Prior history of GI bleeds/ulcers, liver or kidney disease
- •Hypersensitivity to diclofenac or other NSAID drugs (including aspirin)
- •Females who are pregnant or breast feeding
- •Patients participating or having been involved in other clinical investigations during the three months preceding the entry of this study
研究组 & 干预措施
Flector Patch
Experimental
Flector Patch is a transdermal delivery system containing 180 mg of diclofenac hydroxyethylpyrrolidine. The patch will be used twice-a-day for up to two weeks, or until pain resolution, whichever comes first.
干预措施: Diclofenac hydroxyethylpyrrolidine (Drug)
结局指标
主要结局
Dermatologic Assessment at the Patch Application Site
时间窗: Up to 2 weeks, depending upon pain resolution
None - 0; Faint redness - 1; Moderate redness - 2; Intense redness - 3; Redness with edema or papules - 4; Redness with weeping vesicles, blisters or bullae - 5; Redness with extension of effect beyond margin of contact site - 6.
次要结局
- Patient Assessment of Pain on a 6-point Scale(Up to 2 weeks, depending upon pain resolution)
- Plasma Concentration of Diclofenac(Day 2 and either Day 4, 7 or 14, depending upon pain resolution)
- Investigator Assessment of the Global Response to Therapy on a 5-point Scale(Up to 2 weeks, depending upon pain resolution)
研究者
研究点 (10)
Loading locations...
相似试验
招募中
3 期
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BHemophilia BHemophilia ANCT05611801Pfizer100
已完成
4 期
A Clinical Study to Assess the Efficacy and Safety of a Healing Ointment on Diaper RashDiaper RashNCT06015217Galderma R&D26
已完成
3 期
Seasonal Allergic Rhinitis In Pediatric SubjectsRhinitis, Allergic, PerennialNCT00107757GlaxoSmithKline576
已完成
不适用
Pilot Study of a Novel IPL for Removal of Unwanted Fine Body HairHypertrichosisNCT01912950Cutera Inc.11
招募中
早期 1 期
CS-206 in Patients With Sickle Cell DiseaseSickle Cell DiseaseNCT06565026CorrectSequence Therapeutics Co., Ltd5